Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vishal Navani

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
BMJ Quality Improvement Reports|January 7, 2016
Improving the inpatient oncology experience through a new consultant ward roundVishal Navani
Biochimica Et Biophysica Acta. Reviews on Cancer|January 20, 2022
Find the path of least resistance: Adaptive therapy to delay treatment failure and improve outcomesCraig Gedye, Vishal Navani
JAMA Oncology|November 18, 2021
Treatment Selection in First-line Metastatic Renal Cell Carcinoma-The Contemporary Treatment Paradigm in the Age of Combination Therapy: A ReviewVishal Navani, Daniel Y C Heng
BMJ Case Reports|June 5, 2013
Guillain-Barre syndrome as a paraneoplastic manifestation of disseminated squamous cell carcinomaVishal Navani, Daniel Webster, Sion K Williams, et al.
Cancer Drug Resistance (Alhambra, Calif.)|July 17, 2023
Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitorsSunil Samnani, Faraz Sachedina, Mehul Gupta, et al.
British Journal of Clinical Pharmacology|May 9, 2020
Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of responseVishal Navani, Moira C Graves, Nikola A Bowden, et al.
Endocrinology, Diabetes & Metabolism Case Reports|October 21, 2021
Castration failure in prostate carcinoma due to a functioning adrenocortical carcinomaVishal Navani, James F Lynam, Steven Smith, et al.
Clinical Lung Cancer|February 1, 2025
Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Practical Guide of Current ControversiesWilliam J Phillips, Ashley Jackson, Biniam Kidane, et al.
JTO Clinical and Research Reports|March 14, 2023
Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in <i>BRAF</i> Mutation-Positive NSCLCAmanda J W Gibson, Aliyah Pabani, Michelle L Dean, et al.
Current Oncology (Toronto, Ont.)|May 24, 2024
Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for <i>EGFR</i> Mutation-Positive Patients Treated with First-Line OsimertinibAmanda Jane Williams Gibson, Michelle Liane Dean, Ishjot Litt, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
BMJ Quality Improvement Reports|January 7, 2016
Improving the inpatient oncology experience through a new consultant ward roundVishal Navani
Biochimica Et Biophysica Acta. Reviews on Cancer|January 20, 2022
Find the path of least resistance: Adaptive therapy to delay treatment failure and improve outcomesCraig Gedye, Vishal Navani
JAMA Oncology|November 18, 2021
Treatment Selection in First-line Metastatic Renal Cell Carcinoma-The Contemporary Treatment Paradigm in the Age of Combination Therapy: A ReviewVishal Navani, Daniel Y C Heng
BMJ Case Reports|June 5, 2013
Guillain-Barre syndrome as a paraneoplastic manifestation of disseminated squamous cell carcinomaVishal Navani, Daniel Webster, Sion K Williams, et al.
Cancer Drug Resistance (Alhambra, Calif.)|July 17, 2023
Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitorsSunil Samnani, Faraz Sachedina, Mehul Gupta, et al.
British Journal of Clinical Pharmacology|May 9, 2020
Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of responseVishal Navani, Moira C Graves, Nikola A Bowden, et al.
Endocrinology, Diabetes & Metabolism Case Reports|October 21, 2021
Castration failure in prostate carcinoma due to a functioning adrenocortical carcinomaVishal Navani, James F Lynam, Steven Smith, et al.
Clinical Lung Cancer|February 1, 2025
Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Practical Guide of Current ControversiesWilliam J Phillips, Ashley Jackson, Biniam Kidane, et al.
JTO Clinical and Research Reports|March 14, 2023
Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in <i>BRAF</i> Mutation-Positive NSCLCAmanda J W Gibson, Aliyah Pabani, Michelle L Dean, et al.
Current Oncology (Toronto, Ont.)|May 24, 2024
Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for <i>EGFR</i> Mutation-Positive Patients Treated with First-Line OsimertinibAmanda Jane Williams Gibson, Michelle Liane Dean, Ishjot Litt, et al.
Pageof 4